SBIR/STTR Research Award
A Novel Mechanism of Action Natural Product for Treatment of Drug-Resistant Gonorrhea
Award amount
$580,747Program and phase
SBIR · Phase IAward year
2024Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- CFD Research Corporation
- Proposal award date
- 2024-04-18
- Contract end date
- 2026-03-31
- UEI
- V3KCP1HNFM33
- Solicitation number
- PA23-230
- Topic code
- NIAID
Research abstract
Project Summary/Abstract: This project seeks to develop a new class of antibiotics against Neisseria gonorrhoeae (NG). NG is considered to be of the highest threat level by the CDC due to its propensity to rapidly develop drug resistance. CFD Research has discovered a novel natural product (NP) with potent NG activity, which we seek to develop here. Aim 1 will build on our established medicinal chemistry program to diversify and optimize the NP’s scaffold for improved potency, cytotoxicity and drug-like properties. Aim 2 will test the in vivo efficacy of the best analogues from Aim 1 in an established mouse model of NG infection. During Phase II, these data will drive further medicinal chemistry design and synthesis of a lead series. Mechanism of action will be elucidated. Followed by in vivo toxicity, and pharmacokinetics to produce an optimized lead compound for further preclinical development as a novel NG antibiotic.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Multiphysics Modeling Framework for Raindrop-Induced Material Damage
- Ground Technologies for Surface Operation Risk Mitigation
- Supportive Tactical Aide Foresight Framework (STAFF)
- Soil Cohesion Effects on Cratering and Transport of Regolith due to Plume-Surface Interaction
- Modular and Scalable Machine Learning Framework for Infrared Search and Track
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
Research funding history
947 SBIR/STTR records share this UEI (1987–2026). Reported award amounts total $350,893,199. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Defense, National Aeronautics and Space Administration, Department of Health and Human Services, National Science Foundation, Department of Commerce, Department of Energy